Chapter 11.20 : Interferon Gamma Enzyme-Linked Immunosorbent Spot Assay

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Interferon Gamma Enzyme-Linked Immunosorbent Spot Assay, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555818814/9781555818814_Chap11.20-1.gif /docserver/preview/fulltext/10.1128/9781555818814/9781555818814_Chap11.20-2.gif


The enzyme-linked immunosorbent spot (ELISpot) assay was described more than 25 years ago for the detection of specific immune cells at the single-cell level. The utility of the interferon gamma (IFN-γ) ELISpot assay in detecting antigen-specific T cells was initially demonstrated in models of autoimmune and infectious diseases. Optimization of the assay through the introduction of specifically designed antibodies, 96-well plates, substrate kits, and other modifications has broadened the potential uses for the IFN-γ ELISpot assay. Today, it is being used for a wide range of applications, including monitoring responses in patients with cancer undergoing immunotherapeutic treatment and monitoring specific immune response patterns in patients with infectious, neoplastic, or autoimmune diseases. Additionally, it has been an important tool in the identification of immunodominant epitopes in HIV and infections, as well as in the development of specific vaccine strategies ( ).

Citation: Leber A. 2016. Interferon Gamma Enzyme-Linked Immunosorbent Spot Assay, p 11.20.1-11.20.8. In Clinical Microbiology Procedures Handbook, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818814.ch11.20
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of Figure 11.20–1
Figure 11.20–1

Plate layout example.

Citation: Leber A. 2016. Interferon Gamma Enzyme-Linked Immunosorbent Spot Assay, p 11.20.1-11.20.8. In Clinical Microbiology Procedures Handbook, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818814.ch11.20
Permissions and Reprints Request Permissions
Download as Powerpoint


1. Russell ND, Hudgens MG, Ha R, Havenar-Daughton C, McElrath MJ. 2003. Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity. J Infect Dis 187: 226242.
2. Dubey S, Clair J, Fu T-M, Guan L, Long R, Mogg R, Anderson K, Collins KB, Gaunt C, Fernandez VR, Zhu L, Kierstead L, Thaler S, Gupta SB, Straus W, Mehrotra D, Tobery TW, Casimiro DR, Shiver JW. 2007. Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay. J Acquir Immune Defic Syndr 45: 2027.
3. Weinberg A, Betensky RA, Zhang L, Ray G. 1998. Effect of shipment, storage, anticoagulant, and cell separation on lymphocyte proliferation assays for human immunodeficiency virus-infected patients. Clin Diagn Lab Immunol 5: 804807.
4. Disis ML, Rosa DeLa C, Goodell V, Kuan L-Y, Chang JCC, Kuus-Reichel K, Clay TM, Kim Lyerly H, Bhatia S, Ghanekar SA, Maino VC, Maecker HT. 2006. Maximizing the retention of antigen specific lymphocyte function after cryopreservation. J Immunol Methods 308: 1318.
5. Smith JG, Joseph HR, Green T, Field JA, Wooters M, Kaufhold RM, Antonello J, Caulfield MJ. 2007. Establishing acceptance criteria for cell-mediated-immunity assays using frozen peripheral blood mononuclear cells stored under optimal and suboptimal conditions. Clin Vaccine Immunol 14: 527537.
6. Bull M, Lee D, Stucky J, Chiu Y-L, Rubin A, Horton H, McElrath MJ. 2007. Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. J Immunol Methods 322: 5769.
7. Janetzki S, Cox JH, Oden N, Ferrari G. 2005. Standardization and validation issues of the ELISPOT assay. Methods Mol Biol 302: 5186.
8. Ezzelle J, Rodriguez-Chavez IR, Darden JM, Stirewalt M, Kunwar N, Hitchcock R, Walter T, D’Souza MP. 2008. Guidelines on good clinical laboratory practice: bridging operations between research and clinical research laboratories. J Pharm Biomed Anal 46: 1829.
9. Sarzotti-Kelsoe M, Cox J, Cleland N, Denny T, Hural J, Needham L, Ozaki D, Rodriguez-Chavez IR, Stevens G, Stiles T, Tarragona-Fiol T, Simkins A. 2009. Evaluation and recommendations on good clinical laboratory practice guidelines for phase I–III clinical trials. PLoS Med 6( 5): e1000067.
10. Code of Federal Regulations. 2015. Code of Federal Regulations, Part 58. Good Laboratory Practice for Nonclinical Laboratory Studies. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRsearch.cfm?CFRPart=58.
11. Weinberg A, Song LY, Wilkening CL, Fenton T, Hural J, Louzao R, Ferrari G, Etter PE, Berrong M, Canniff JD, Carter D, Defawe OD, Garcia A, Garrelts TL, Gelman R, Lambrecht LK, Pahwa S, Pilakka-Kanthikeel S, Shugarts DL, Tustin NB. 2010. Optimization of storage and shipment of cryopreserved peripheral blood mononuclear cells from HIV-infected and uninfected individuals for ELISPOT assays. J Immunol Methods 363: 4250.
12. Gill DK, Huang Y, Levine GL, Sambor A, Carter DK, Sato A, Kopycinski J, Hayes P, Hahn B, Birungi J, Tarragona-Fiol T, Wan H, Randles M, Cooper AR, Ssemaganda A, Clark L, Kaleebu P, Self SG, Koup R, Wood B, McElrath MJ, Cox JH, Hural J, Gilmour J. 2010. Equivalence of ELISpot assays demonstrated between major HIV network laboratories. PLoS One 5( 12): e14330.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error